{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 23310, "items": [{"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T16:44:57Z", "timestamp": 1574527497291}, "reference-count": 61, "publisher": "Informa Healthcare", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Expert Opinion on Investigational Drugs"], "published-print": {"date-parts": [[2013, 3]]}, "DOI": "10.1517/13543784.2013.761974", "type": "journal-article", "created": {"date-parts": [[2013, 1, 15]], "date-time": "2013-01-15T10:22:43Z", "timestamp": 1358245363000}, "page": "379-387", "source": "Crossref", "is-referenced-by-count": 8, "title": ["Radium-223 for the treatment of prostate cancer"], "prefix": "10.1517", "volume": "22", "author": [{"given": "Shaista", "family": "Hafeez", "sequence": "first", "affiliation": []}, {"given": "Christopher", "family": "Parker", "sequence": "additional", "affiliation": []}], "member": "3197", "published-online": {"date-parts": [[2013, 1, 15]]}, "reference": [{"key": "CIT0001", "DOI": "10.3322/caac.20073", "doi-asserted-by": "publisher"}, {"key": "CIT0002", "DOI": "10.1586/era.12.59", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1053/j.seminoncol.2010.10.002", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1038/nrc867", "doi-asserted-by": "publisher"}, {"key": "CIT0005", "DOI": "10.1007/s00520-006-0203-x", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1002/cncr.24395", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "DOI": "10.1056/NEJM198908173210702", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1056/NEJM199810083391504", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1056/NEJMoa040720", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1056/NEJMoa041318", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1002/cncr.23473", "doi-asserted-by": "publisher"}, {"issue": "6", "key": "CIT0012", "doi-asserted-by": "crossref", "first-page": "1756", "DOI": "10.1200/JCO.1996.14.6.1756", "volume": "14", "author": "Tannock IF", "year": "1996", "journal-title": "J Clin Oncol"}, {"key": "CIT0016", "DOI": "10.1016/S0140-6736(10)61389-X", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1200/JCO.2005.03.1435", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1016/S0090-4295(98)00173-3", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "author": "Wilkins A", "year": "2012", "journal-title": "BJU Int"}, {"key": "CIT0021", "DOI": "10.1056/NEJMoa1014618", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "author": "Ryan CJ", "volume": "30", "first-page": "LBA4518", "year": "2012", "journal-title": "J Clin Oncol", "DOI": "10.1200/jco.2012.30.18_suppl.lba4518", "doi-asserted-by": "crossref"}, {"key": "CIT0025", "DOI": "10.1056/NEJMoa1207506", "doi-asserted-by": "publisher"}, {"key": "CIT0027", "DOI": "10.1200/JCO.2005.04.5252", "doi-asserted-by": "publisher"}, {"key": "CIT0028", "DOI": "10.1038/nbt0209-129", "doi-asserted-by": "publisher"}, {"key": "CIT0029", "DOI": "10.1002/cncr.24429", "doi-asserted-by": "publisher"}, {"key": "CIT0030", "DOI": "10.1016/S0936-6555(97)80070-2", "doi-asserted-by": "publisher"}, {"key": "CIT0031", "DOI": "10.1016/S0360-3016(02)04147-0", "doi-asserted-by": "publisher"}, {"key": "CIT0032", "DOI": "10.1016/S0936-6555(03)00113-4", "doi-asserted-by": "publisher"}, {"key": "CIT0033", "DOI": "10.1016/j.radonc.2004.09.017", "doi-asserted-by": "publisher"}, {"key": "CIT0034", "DOI": "10.1016/j.clon.2011.11.004", "doi-asserted-by": "publisher"}, {"key": "CIT0035", "DOI": "10.1016/j.ijrobp.2003.10.006", "doi-asserted-by": "publisher"}, {"key": "CIT0036", "DOI": "10.1016/S0360-3016(01)01495-X", "doi-asserted-by": "publisher"}, {"key": "CIT0037", "DOI": "10.1016/S0936-6555(05)80975-6", "doi-asserted-by": "publisher"}, {"key": "CIT0038", "DOI": "10.1093/jnci/djh141", "doi-asserted-by": "publisher"}, {"key": "CIT0039", "DOI": "10.1200/JCO.2003.05.147", "doi-asserted-by": "publisher"}, {"key": "CIT0040", "DOI": "10.1016/S0140-6736(10)62344-6", "doi-asserted-by": "publisher"}, {"key": "CIT0041", "DOI": "10.1002/1097-0142(20000615)88:12+<2934::AID-CNCR9>3.0.CO;2-S", "doi-asserted-by": "publisher"}, {"issue": "11", "key": "CIT0042", "first-page": "1839", "volume": "34", "author": "Collins C", "year": "1993", "journal-title": "J Nucl Med"}, {"key": "CIT0043", "DOI": "10.1016/j.urology.2004.01.034", "doi-asserted-by": "publisher"}, {"key": "CIT0044", "DOI": "10.1002/cncr.22431", "doi-asserted-by": "publisher"}, {"key": "CIT0045", "DOI": "10.1016/S1470-2045(05)70206-0", "doi-asserted-by": "publisher"}, {"key": "CIT0046", "DOI": "10.1200/JCO.2008.18.9811", "doi-asserted-by": "publisher"}, {"key": "CIT0048", "DOI": "10.1158/1078-0432.CCR-06-0841", "doi-asserted-by": "publisher"}, {"key": "CIT0049", "author": "I.C.R.P", "year": "2003", "volume-title": "Publication 92: Relative Biological Effectiveness (REBE), Quality Factor (Q) and Radiation Weighting Factor (wR)"}, {"key": "CIT0050", "DOI": "10.1007/s002590050306", "doi-asserted-by": "publisher"}, {"issue": "11", "key": "CIT0051", "first-page": "3120", "volume": "62", "author": "Henriksen G", "year": "2002", "journal-title": "Cancer Res"}, {"key": "CIT0052", "DOI": "10.1158/1078-0432.CCR-04-2244", "doi-asserted-by": "publisher"}, {"key": "CIT0053", "DOI": "10.2174/1874471011205030244", "doi-asserted-by": "publisher"}, {"issue": "10", "key": "CIT0054", "doi-asserted-by": "crossref", "first-page": "661", "DOI": "10.1524/ract.2001.89.10.661", "volume": "89", "author": "Henriksen G", "year": "2001", "journal-title": "Radiochim Acta"}, {"issue": "15", "key": "CIT0056", "doi-asserted-by": "crossref", "first-page": "e15009", "DOI": "10.1200/jco.2010.28.15_suppl.e15009", "volume": "28", "author": "Lewington V", "year": "2010", "journal-title": "J Clin Oncol (Meeting Abstracts)"}, {"key": "CIT0057", "DOI": "10.1097/MNM.0b013e328353bb6e", "doi-asserted-by": "publisher"}, {"key": "CIT0058", "DOI": "10.1016/S1470-2045(07)70147-X", "doi-asserted-by": "publisher"}, {"key": "CIT0059", "author": "Nilsson S", "year": "2012", "journal-title": "Clin Genitourin Cancer"}, {"key": "CIT0060", "DOI": "10.1016/j.ejca.2011.12.023", "doi-asserted-by": "publisher"}, {"key": "CIT0061", "DOI": "10.1016/j.eururo.2012.09.008", "doi-asserted-by": "publisher"}, {"issue": "7", "key": "CIT0063", "first-page": "abstract 49", "volume": "29", "author": "Nilsson S", "year": "2011", "journal-title": "J Clin Oncol"}, {"issue": "18", "key": "CIT0064", "doi-asserted-by": "crossref", "first-page": "LBA4512", "DOI": "10.1200/jco.2012.30.18_suppl.lba4512", "volume": "30", "author": "Parker C", "year": "2012", "journal-title": "J Clin Oncol"}, {"key": "CIT0065", "author": "Parker C", "year": "2012", "journal-title": "NCRI"}, {"key": "CIT0066", "DOI": "10.1093/rheumatology/ken060", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "CIT0067", "first-page": "79", "volume": "43", "author": "Sciuto R", "year": "2002", "journal-title": "J Nucl Med"}, {"key": "CIT0068", "DOI": "10.1016/S0140-6736(00)03639-4", "doi-asserted-by": "publisher"}, {"key": "CIT0069", "DOI": "10.1200/JCO.2008.20.4164", "doi-asserted-by": "publisher"}, {"key": "CIT0071", "DOI": "10.1016/S1470-2045(12)70372-8", "doi-asserted-by": "publisher"}, {"key": "CIT0072", "DOI": "10.1007/s13167-011-0138-2", "doi-asserted-by": "publisher"}], "container-title": ["Expert Opinion on Investigational Drugs"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1517/13543784.2013.761974", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 21]], "date-time": "2017-06-21T05:39:57Z", "timestamp": 1498023597000}, "score": 36.708115, "issued": {"date-parts": [[2013, 1, 15]]}, "references-count": 61, "journal-issue": {"published-online": {"date-parts": [[2013, 1, 21]]}, "published-print": {"date-parts": [[2013, 3]]}, "issue": "3"}, "alternative-id": ["10.1517/13543784.2013.761974"], "URL": "http://dx.doi.org/10.1517/13543784.2013.761974", "relation": {"cites": []}, "ISSN": ["1354-3784", "1744-7658"], "issn-type": [{"value": "1354-3784", "type": "print"}, {"value": "1744-7658", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T04:03:05Z", "timestamp": 1574827385534}, "reference-count": 39, "publisher": "Informa UK Limited", "issue": "9", "funder": [{"name": "National Institute for Health Research Royal Marsden and Institute for Cancer Research Biomedical Research Centre", "award": []}], "content-domain": {"domain": ["www.tandfonline.com"], "crossmark-restriction": true}, "short-container-title": ["Expert Review of Anticancer Therapy"], "published-print": {"date-parts": [[2016, 9]]}, "DOI": "10.1080/14737140.2016.1222273", "type": "journal-article", "created": {"date-parts": [[2016, 8, 8]], "date-time": "2016-08-08T13:36:59Z", "timestamp": 1470663419000}, "page": "911-918", "update-policy": "http://dx.doi.org/10.1080/tandf_crossmark_01", "source": "Crossref", "is-referenced-by-count": 5, "title": ["The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer"], "prefix": "10.1080", "volume": "16", "author": [{"given": "James M.", "family": "Wilson", "sequence": "first", "affiliation": []}, {"given": "Christopher", "family": "Parker", "sequence": "additional", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2016, 8, 24]]}, "reference": [{"key": "CIT0001", "DOI": "10.3322/caac.21262", "doi-asserted-by": "publisher"}, {"key": "CIT0002", "DOI": "10.1056/NEJMoa040720", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1056/NEJMoa1405095", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1016/j.eururo.2014.02.056", "doi-asserted-by": "publisher"}, {"key": "CIT0005", "DOI": "10.1038/nrc867", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1053/j.seminoncol.2010.10.002", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "DOI": "10.1038/pcan.2011.7", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1093/jnci/djh141", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1002/(SICI)1097-0142(19971015)80:8+<1674::AID-CNCR18>3.0.CO;2-X", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1200/JCO.2008.19.2146", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "DOI": "10.1016/0360-3016(93)90309-J", "doi-asserted-by": "publisher"}, {"key": "CIT0012", "author": "Larsen RH", "volume": "40", "first-page": "1197", "year": "1999", "journal-title": "J Nucl Med"}, {"key": "CIT0013", "author": "Henriksen G", "volume": "44", "first-page": "252", "year": "2003", "journal-title": "J Nucl Med"}, {"key": "CIT0014", "DOI": "10.1111/j.1749-6632.1955.tb35369.x", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "DOI": "10.1667/0033-7587(2000)153[0093:IOMBTI]2.0.CO;2", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "DOI": "10.1097/00004032-197807000-00002", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "DOI": "10.1016/j.icrp.2008.10.001", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "author": "Henriksen G", "volume": "62", "first-page": "3120", "year": "2002", "journal-title": "Cancer Res"}, {"key": "CIT0019", "DOI": "10.1158/1078-0432.CCR-04-2244", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "DOI": "10.2967/jnumed.115.157123", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.2307/3576005", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1016/j.nucmedbio.2005.05.009", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "DOI": "10.1097/HP.0b013e3182a82b37", "doi-asserted-by": "publisher"}, {"key": "CIT0024", "DOI": "10.1016/S1470-2045(07)70147-X", "doi-asserted-by": "publisher"}, {"key": "CIT0025", "DOI": "10.1016/j.eururo.2012.09.008", "doi-asserted-by": "publisher"}, {"key": "CIT0026", "DOI": "10.1056/NEJMoa1213755", "doi-asserted-by": "publisher"}, {"key": "CIT0027", "DOI": "10.1016/S1470-2045(14)70474-7", "doi-asserted-by": "publisher"}, {"key": "CIT0028", "DOI": "10.1016/S1470-2045(14)70183-4", "doi-asserted-by": "publisher"}, {"key": "CIT0029", "DOI": "10.1016/j.clon.2009.07.011", "doi-asserted-by": "publisher"}, {"key": "CIT0030", "DOI": "10.1016/j.ctrv.2012.03.006", "doi-asserted-by": "publisher"}, {"key": "CIT0031", "DOI": "10.1016/j.eururo.2016.06.002", "doi-asserted-by": "publisher"}, {"key": "CIT0032", "DOI": "10.1056/NEJMoa1014618", "doi-asserted-by": "publisher"}, {"key": "CIT0033", "DOI": "10.1056/NEJMoa1207506", "doi-asserted-by": "publisher"}, {"key": "CIT0034", "DOI": "10.1016/S1470-2045(14)71026-5", "doi-asserted-by": "publisher"}, {"key": "CIT0035", "DOI": "10.1016/S0140-6736(10)61389-X", "doi-asserted-by": "publisher"}, {"key": "CIT0036", "DOI": "10.1093/annonc/mdw065", "doi-asserted-by": "publisher"}, {"key": "CIT0037", "DOI": "10.1056/NEJMoa1503747", "doi-asserted-by": "publisher"}, {"key": "CIT0039", "DOI": "10.1016/j.eururo.2014.02.056", "doi-asserted-by": "publisher"}, {"key": "CIT0040", "DOI": "10.1056/NEJMoa1001294", "doi-asserted-by": "publisher"}], "container-title": ["Expert Review of Anticancer Therapy"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1080/14737140.2016.1222273", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 13]], "date-time": "2016-12-13T15:24:46Z", "timestamp": 1481642686000}, "score": 35.685467, "issued": {"date-parts": [[2016, 8, 24]]}, "references-count": 39, "journal-issue": {"published-online": {"date-parts": [[2016, 7, 5]]}, "published-print": {"date-parts": [[2016, 9]]}, "issue": "9"}, "alternative-id": ["10.1080/14737140.2016.1222273"], "URL": "http://dx.doi.org/10.1080/14737140.2016.1222273", "relation": {"cites": []}, "ISSN": ["1473-7140", "1744-8328"], "issn-type": [{"value": "1473-7140", "type": "print"}, {"value": "1744-8328", "type": "electronic"}], "assertion": [{"value": "The publishing and review policy for this title is described in its Aims & Scope.", "order": 1, "name": "peerreview_statement", "label": "Peer Review Statement"}, {"value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=iery20", "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=iery20", "order": 2, "name": "aims_and_scope_url", "label": "Aim & Scope"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T05:44:27Z", "timestamp": 1574487867478}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 5, 1]], "date-time": "2012-05-01T00:00:00Z", "timestamp": 1335830400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Radiotherapy and Oncology"], "published-print": {"date-parts": [[2012, 5]]}, "DOI": "10.1016/s0167-8140(12)70875-7", "type": "journal-article", "created": {"date-parts": [[2012, 7, 13]], "date-time": "2012-07-13T07:01:07Z", "timestamp": 1342162867000}, "page": "S214", "source": "Crossref", "is-referenced-by-count": 0, "title": ["SP-0536 RADIUM-223 IN THE TREATMENT OF ADVANCED PROSTATE CANCER"], "prefix": "10.1016", "volume": "103", "author": [{"given": "C.", "family": "Parker", "sequence": "first", "affiliation": []}, {"given": "V.", "family": "Lewington", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Radiotherapy and Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0167814012708757?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0167814012708757?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 22]], "date-time": "2018-11-22T05:55:57Z", "timestamp": 1542866157000}, "score": 34.067787, "issued": {"date-parts": [[2012, 5]]}, "references-count": 0, "alternative-id": ["S0167814012708757"], "URL": "http://dx.doi.org/10.1016/s0167-8140(12)70875-7", "ISSN": ["0167-8140"], "issn-type": [{"value": "0167-8140", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T17:01:57Z", "timestamp": 1575219717723}, "reference-count": 69, "publisher": "Springer Science and Business Media LLC", "issue": "1", "license": [{"URL": "https://creativecommons.org/licenses/by/4.0", "start": {"date-parts": [[2018, 1, 3]], "date-time": "2018-01-03T00:00:00Z", "timestamp": 1514937600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Prostate Cancer Prostatic Dis"], "published-print": {"date-parts": [[2018, 4]]}, "DOI": "10.1038/s41391-017-0020-y", "type": "journal-article", "created": {"date-parts": [[2018, 1, 3]], "date-time": "2018-01-03T20:52:37Z", "timestamp": 1515012757000}, "page": "37-47", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 17, "title": ["Current approaches to incorporation of radium-223 in clinical practice"], "prefix": "10.1038", "volume": "21", "author": [{"given": "Chris", "family": "Parker", "sequence": "first", "affiliation": []}, {"given": "Axel", "family": "Heidenreich", "sequence": "additional", "affiliation": []}, {"given": "Sten", "family": "Nilsson", "sequence": "additional", "affiliation": []}, {"given": "Neal", "family": "Shore", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2018, 1, 3]]}, "reference": [{"key": "20_CR1", "doi-asserted-by": "publisher", "first-page": "1502", "DOI": "10.1056/NEJMoa040720", "volume": "351", "author": "IF Tannock", "year": "2004", "unstructured": "Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.", "journal-title": "N Engl J Med."}, {"key": "20_CR2", "doi-asserted-by": "publisher", "first-page": "293", "DOI": "10.1016/j.urology.2012.04.007", "volume": "80", "author": "SJ Freedland", "year": "2012", "unstructured": "Freedland SJ, Richhariya A, Wang H, Chung K, Shore ND. Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology. 2012;80:293\u20138.", "journal-title": "Urology."}, {"key": "20_CR3", "doi-asserted-by": "publisher", "first-page": "270", "DOI": "10.1016/j.eururo.2013.10.055", "volume": "65", "author": "CJ Pezaro", "year": "2014", "unstructured": "Pezaro CJ, Omlin A, Lorente D, Nava Rodrigues D, Ferraldeschi R, Bianchini D, et al. Visceral disease in castration-resistant prostate cancer. Eur Urol. 2014;65:270\u20133.", "journal-title": "Eur Urol."}, {"key": "20_CR4", "first-page": "E373", "volume": "14", "author": "HS Smith", "year": "2011", "unstructured": "Smith HS. Painful osseous metastases. Pain Physician. 2011;14:E373\u2013403.", "journal-title": "Pain Physician."}, {"key": "20_CR5", "doi-asserted-by": "publisher", "first-page": "6243s", "DOI": "10.1158/1078-0432.CCR-06-0931", "volume": "12", "author": "RE Coleman", "year": "2006", "unstructured": "Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s\u201349s.", "journal-title": "Clin Cancer Res."}, {"key": "20_CR6", "doi-asserted-by": "publisher", "first-page": "1547", "DOI": "10.1038/bjc.2012.436", "volume": "107", "author": "A Som", "year": "2012", "unstructured": "Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, et al. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer. 2012;107:1547\u201353.", "journal-title": "Br J Cancer."}, {"key": "20_CR7", "doi-asserted-by": "publisher", "first-page": "E70", "DOI": "10.1111/bju.12717", "volume": "114", "author": "C Tait", "year": "2014", "unstructured": "Tait C, Moore D, Hodgson C, Brown M, Morris T, Growcott J, et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int. 2014;114:E70\u20133.", "journal-title": "BJU Int."}, {"key": "20_CR8", "doi-asserted-by": "publisher", "first-page": "675", "DOI": "10.1016/j.eururo.2016.03.017", "volume": "70", "author": "CP Evans", "year": "2016", "unstructured": "Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, et al. The PREVAIL study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naive metastatic castration-resistant prostate cancer. Eur Urol. 2016;70:675\u201383.", "journal-title": "Eur Urol."}, {"key": "20_CR9", "doi-asserted-by": "publisher", "first-page": "S11", "DOI": "10.5489/cuaj.274", "volume": "7", "author": "J Asselah", "year": "2013", "unstructured": "Asselah J, Sperlich C. Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: questions of choice. Can Urol Assoc J. 2013;7:S11\u20137.", "journal-title": "Can Urol Assoc J."}, {"key": "20_CR10", "doi-asserted-by": "publisher", "first-page": "467", "DOI": "10.1016/j.eururo.2013.11.002", "volume": "65", "author": "A Heidenreich", "year": "2014", "unstructured": "Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467\u201379.", "journal-title": "Eur Urol."}, {"key": "20_CR11", "unstructured": "National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer version 1.2016. Fort Washington, PA: National Comprehensive Cancer Network; 2016."}, {"key": "20_CR12", "unstructured": "Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer: AUA guideline. American Urological Association. \n                    https://www.auanet.org/guidelines/castration-resistant-prostate-cancer\n                    \n                  . Accessed 18 April 2017."}, {"key": "20_CR13", "doi-asserted-by": "publisher", "first-page": "1444", "DOI": "10.1016/j.juro.2015.10.086", "volume": "195", "author": "WT Lowrance", "year": "2016", "unstructured": "Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS. Castration-resistant prostate cancer: AUA guideline amendment 2015. J Urol. 2016;195:1444\u201352.", "journal-title": "J Urol."}, {"key": "20_CR14", "doi-asserted-by": "publisher", "first-page": "v69", "DOI": "10.1093/annonc/mdv222", "volume": "26", "author": "C Parker", "year": "2015", "unstructured": "Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v69\u201377.", "journal-title": "Ann Oncol."}, {"key": "20_CR15", "doi-asserted-by": "publisher", "first-page": "90", "DOI": "10.5489/cuaj.2526", "volume": "9", "author": "F Saad", "year": "2015", "unstructured": "Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, et al. The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). Can Urol Assoc J. 2015;9:90\u20136.", "journal-title": "Can Urol Assoc J."}, {"key": "20_CR16", "doi-asserted-by": "publisher", "first-page": "424", "DOI": "10.1056/NEJMoa1405095", "volume": "371", "author": "TM Beer", "year": "2014", "unstructured": "Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.", "journal-title": "N Engl J Med."}, {"key": "20_CR17", "doi-asserted-by": "publisher", "first-page": "1187", "DOI": "10.1056/NEJMoa1207506", "volume": "367", "author": "HI Scher", "year": "2012", "unstructured": "Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.", "journal-title": "N Engl J Med."}, {"key": "20_CR18", "doi-asserted-by": "publisher", "first-page": "213", "DOI": "10.1056/NEJMoa1213755", "volume": "369", "author": "C Parker", "year": "2013", "unstructured": "Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.", "journal-title": "N Engl J Med."}, {"key": "20_CR19", "doi-asserted-by": "publisher", "first-page": "1147", "DOI": "10.1016/S0140-6736(10)61389-X", "volume": "376", "author": "JS Bono de", "year": "2010", "unstructured": "de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.", "journal-title": "Lancet."}, {"key": "20_CR20", "doi-asserted-by": "publisher", "first-page": "138", "DOI": "10.1056/NEJMoa1209096", "volume": "368", "author": "CJ Ryan", "year": "2013", "unstructured": "Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.", "journal-title": "N Engl J Med."}, {"key": "20_CR21", "doi-asserted-by": "publisher", "first-page": "1995", "DOI": "10.1056/NEJMoa1014618", "volume": "364", "author": "JS Bono de", "year": "2011", "unstructured": "de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.", "journal-title": "N Engl J Med."}, {"key": "20_CR22", "doi-asserted-by": "publisher", "first-page": "411", "DOI": "10.1056/NEJMoa1001294", "volume": "363", "author": "PW Kantoff", "year": "2010", "unstructured": "Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.", "journal-title": "N Engl J Med."}, {"key": "20_CR23", "doi-asserted-by": "publisher", "first-page": "152", "DOI": "10.1016/S1470-2045(14)71205-7", "volume": "16", "author": "CJ Ryan", "year": "2015", "unstructured": "Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.", "journal-title": "Lancet Oncol."}, {"key": "20_CR24", "doi-asserted-by": "publisher", "first-page": "738", "DOI": "10.1016/S1470-2045(14)70183-4", "volume": "15", "author": "O Sartor", "year": "2014", "unstructured": "Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738\u201346.", "journal-title": "Lancet Oncol."}, {"key": "20_CR25", "doi-asserted-by": "publisher", "first-page": "1397", "DOI": "10.1016/S1470-2045(14)70474-7", "volume": "15", "author": "P Hoskin", "year": "2014", "unstructured": "Hoskin P, Sartor O, O\u2019Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15:1397\u2013406.", "journal-title": "Lancet Oncol."}, {"key": "20_CR26", "doi-asserted-by": "publisher", "first-page": "868", "DOI": "10.1093/annonc/mdw065", "volume": "27", "author": "S Nilsson", "year": "2016", "unstructured": "Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O\u2019Sullivan JM, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27:868\u201374.", "journal-title": "Ann Oncol."}, {"key": "20_CR27", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/j.ejca.2016.10.020", "volume": "71", "author": "C Parker", "year": "2017", "unstructured": "Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, et al. Effect of radium-223 dichloride (Ra-223) on hospitalisation: an analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer. 2017;71:1\u20136.", "journal-title": "Eur J Cancer."}, {"key": "20_CR28", "doi-asserted-by": "publisher", "first-page": "875", "DOI": "10.1016/j.eururo.2016.06.002", "volume": "70", "author": "C Parker", "year": "2016", "unstructured": "Parker C, Finkelstein SE, Michalski JM, O\u2019Sullivan JM, Bruland O, Vogelzang NJ, et al. Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol. 2016;70:875\u201383.", "journal-title": "Eur Urol."}, {"key": "20_CR29", "unstructured": "National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer version 2.2016. Fort Washington, PA: National Comprehensive Cancer Network; 2016."}, {"key": "20_CR30", "doi-asserted-by": "publisher", "first-page": "3436", "DOI": "10.1200/JCO.2013.54.8404", "volume": "32", "author": "E Basch", "year": "2014", "unstructured": "Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014;32:3436\u201348.", "journal-title": "J Clin Oncol."}, {"issue": "15_suppl", "key": "20_CR31", "doi-asserted-by": "publisher", "first-page": "10124", "DOI": "10.1200/JCO.2016.34.15_suppl.10124", "volume": "34", "author": "William K. Oh", "year": "2016", "unstructured": "Oh WK, Tombal BF, Delacruz A, Tomlinson B, Ripley AV, Drudge-Coates L, et al. Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey [abstract]. J Clin Oncol. 2016;34:abst 10124.", "journal-title": "Journal of Clinical Oncology"}, {"key": "20_CR32", "unstructured": "Men Who Speak Up. It\u2019s time to speak up about advanced prostate cancer. Bayer. \n                    https://www.menwhospeakup.com/index.php\n                    \n                  . Accessed 17 April 2017."}, {"key": "20_CR33", "doi-asserted-by": "publisher", "first-page": "2166", "DOI": "10.1093/annonc/mdr587", "volume": "23", "author": "CA Bellera", "year": "2012", "unstructured": "Bellera CA, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166\u201372.", "journal-title": "Ann Oncol."}, {"key": "20_CR34", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1016/j.jgo.2013.08.003", "volume": "5", "author": "E Liuu", "year": "2014", "unstructured": "Liuu E, Canoui-Poitrine F, Tournigand C, Laurent M, Caillet P, Le Thuaut A, et al. Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: the ELCAPA-02 study. J Geriatr Oncol. 2014;5:11\u20139.", "journal-title": "J Geriatr Oncol."}, {"key": "20_CR35", "doi-asserted-by": "publisher", "first-page": "e404", "DOI": "10.1016/S1470-2045(14)70018-X", "volume": "15", "author": "JP Droz", "year": "2014", "unstructured": "Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15:e404\u201314.", "journal-title": "Lancet Oncol."}, {"key": "20_CR36", "doi-asserted-by": "publisher", "first-page": "587", "DOI": "10.1016/S1470-2045(07)70147-X", "volume": "8", "author": "S Nilsson", "year": "2007", "unstructured": "Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587\u201394.", "journal-title": "Lancet Oncol."}, {"key": "20_CR37", "doi-asserted-by": "publisher", "first-page": "182", "DOI": "10.1200/jco.2015.33.7_suppl.182", "volume": "33", "author": "SE Finkelstein", "year": "2015", "unstructured": "Finkelstein SE, Michalski JM, O\u2019Sullivan JM, Parker C, Garcia-Vargas JE, Sartor AO. External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial. J Clin Oncol. 2015;33:182.", "journal-title": "J Clin Oncol."}, {"key": "20_CR38", "unstructured": "Nordquist LT, Shore ND. Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases. Presented at: 2016 ASCO Annual Meeting; June 3\u20137, 2016; Chicago, IL.", "DOI": "10.1200/JCO.2016.34.15_suppl.e16546", "doi-asserted-by": "crossref"}, {"issue": "15_suppl", "key": "20_CR39", "doi-asserted-by": "publisher", "first-page": "TPS5082", "DOI": "10.1200/jco.2015.33.15_suppl.tps5082", "volume": "33", "author": "Matthew Raymond Smith", "year": "2015", "unstructured": "Smith MR, Parker C, Tombal BF, Miller K, Saad F, Fang F, et al. ERA 223: a phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol. 2015;33:abstr TPS5082.", "journal-title": "Journal of Clinical Oncology"}, {"key": "20_CR40", "doi-asserted-by": "publisher", "first-page": "33", "DOI": "10.1002/pros.23246", "volume": "77", "author": "BL Maughan", "year": "2017", "unstructured": "Maughan BL, Luber B, Nadal R, Antonarakis ES. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate. 2017;77:33\u201340.", "journal-title": "Prostate."}, {"key": "20_CR41", "doi-asserted-by": "publisher", "first-page": "T179", "DOI": "10.1530/ERC-16-0422", "volume": "23", "author": "I Coutinho", "year": "2016", "unstructured": "Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer. 2016;23:T179\u201397.", "journal-title": "Endocr Relat Cancer."}, {"key": "20_CR42", "doi-asserted-by": "publisher", "first-page": "64", "DOI": "10.1007/s11864-016-0438-9", "volume": "17", "author": "CE Handy", "year": "2016", "unstructured": "Handy CE, Antonarakis ES. Sequencing treatment for castration-resistant prostate cancer. Curr Treat Options Oncol. 2016;17:64.", "journal-title": "Curr Treat Options Oncol."}, {"key": "20_CR43", "unstructured": "Xofigo (radium-223 dichloride). Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG; 2016."}, {"key": "20_CR44", "doi-asserted-by": "publisher", "first-page": "42", "DOI": "10.1016/j.clgc.2016.07.027", "volume": "15", "author": "NJ Vogelzang", "year": "2017", "unstructured": "Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O\u2019Sullivan JM, Parker C, et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin Genitourin Cancer. 2017;15:42\u201352.", "journal-title": "Clin Genitourin Cancer."}, {"key": "20_CR45", "unstructured": "Xofigo (radium-223 dichloride). Full Prescribing Information, Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ, USA, 2013."}, {"issue": "15_suppl", "key": "20_CR46", "doi-asserted-by": "publisher", "first-page": "5012", "DOI": "10.1200/jco.2015.33.15_suppl.5012", "volume": "33", "author": "Michael J. Morris", "year": "2015", "unstructured": "Morris MJ, Higano CS, Scher HI, Sweeney C, Antonarakis ES, Shevrin DH, et al. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): a phase 1/2a clinical trial [abstract]. J Clin Oncol. 2015;33:abstr 5012.", "journal-title": "Journal of Clinical Oncology"}, {"key": "20_CR47", "unstructured": "Morris MJ, Loriot Y, Sweeney C, Fizazi K, Ryan CJ, Shevrin DH, et al. Updated results: a phase I/IIa randomized trial of radium223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases. Presented at: 2016 ASCO Annual Meeting; June 3\u20137, 2016; Chicago, IL."}, {"issue": "9", "key": "20_CR48", "doi-asserted-by": "publisher", "first-page": "1306", "DOI": "10.1016/S1470-2045(16)30173-5", "volume": "17", "author": "Fred Saad", "year": "2016", "unstructured": "Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17:1306-1316.", "journal-title": "The Lancet Oncology"}, {"key": "20_CR49", "doi-asserted-by": "publisher", "first-page": "289", "DOI": "10.1038/pcan.2017.6", "volume": "20", "author": "D Keizman", "year": "2017", "unstructured": "Keizman D, Fosboel MO, Reichegger H, Peer A, Rosenbaum E, Desax MC, et al. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database. Prostate Cancer Prostatic Dis. 2017;20:289\u201393.", "journal-title": "Prostate Cancer Prostatic Dis."}, {"key": "20_CR50", "unstructured": "Blackledge MD, Kohl DM, Collins DJ, Scurr E, Hughes J, Leach MO, et al. Assessing response heterogeneity following radium 223 administration using whole body diffusion weighted MRI. Presented at: International Society for Magnetic Resonance in Medicine 25th Annual Meeting & Exhibition; April 22\u201327, 2017; Honolulu, HI."}, {"key": "20_CR51", "doi-asserted-by": "publisher", "first-page": "168", "DOI": "10.1148/radiol.2016160646", "volume": "283", "author": "R Perez-Lopez", "year": "2017", "unstructured": "Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, et al. Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study. Radiology. 2017;283:168\u201377.", "journal-title": "Radiology."}, {"key": "20_CR52", "doi-asserted-by": "publisher", "first-page": "717", "DOI": "10.1016/j.urology.2014.11.031", "volume": "85", "author": "ND Shore", "year": "2015", "unstructured": "Shore ND. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist\u2019s perspective. Urology. 2015;85:717\u201324.", "journal-title": "Urology."}, {"key": "20_CR53", "doi-asserted-by": "publisher", "first-page": "1589", "DOI": "10.1093/annonc/mdv257", "volume": "26", "author": "S Gillessen", "year": "2015", "unstructured": "Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26:1589\u2013604.", "journal-title": "Ann Oncol."}, {"issue": "7_suppl", "key": "20_CR54", "doi-asserted-by": "publisher", "first-page": "160", "DOI": "10.1200/jco.2015.33.7_suppl.160", "volume": "33", "author": "Michael J. Morris", "year": "2015", "unstructured": "Morris MJ, Sartor AO, Vogelzang NJ, Shore ND, Cislo P, Bangerter K, et al. Effect of radium-223 dichloride (Ra-223) on pain from US EAP [abstract]. J Clin Oncol. 2015;33:abstr 160.", "journal-title": "Journal of Clinical Oncology"}, {"key": "20_CR55", "doi-asserted-by": "publisher", "first-page": "279", "DOI": "10.2147/JMDH.S81007", "volume": "8", "author": "JF Renzulli 2nd", "year": "2015", "unstructured": "Renzulli JF 2nd, Collins J, Mega A. Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer. J Multidiscip Healthc. 2015;8:279\u201386.", "journal-title": "J Multidiscip Healthc."}, {"key": "20_CR56", "doi-asserted-by": "publisher", "first-page": "1513", "DOI": "10.1056/NEJMoa041318", "volume": "351", "author": "DP Petrylak", "year": "2004", "unstructured": "Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513\u201320.", "journal-title": "N Engl J Med."}, {"key": "20_CR57", "unstructured": "Provenge (sipuleucel-T). Full Prescribing Information, Dendreon Corporation, Seattle, WA, 2014."}, {"key": "20_CR58", "doi-asserted-by": "publisher", "first-page": "850", "DOI": "10.1016/j.eururo.2015.06.039", "volume": "68", "author": "BA Gartrell", "year": "2015", "unstructured": "Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, et al. Metastatic prostate cancer and the bone: significance and therapeutic options. Eur Urol. 2015;68:850\u20138.", "journal-title": "Eur Urol."}, {"key": "20_CR59", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1177/1756287213509677", "volume": "6", "author": "A Omlin", "year": "2014", "unstructured": "Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol. 2014;6:3\u201314.", "journal-title": "Ther Adv Urol."}, {"key": "20_CR60", "doi-asserted-by": "publisher", "first-page": "498", "DOI": "10.1016/j.critrevonc.2015.07.013", "volume": "96", "author": "F Maines", "year": "2015", "unstructured": "Maines F, Caffo O, Veccia A, Trentin C, Tortora G, Galligioni E, et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2015;96:498\u2013506.", "journal-title": "Crit Rev Oncol Hematol."}, {"key": "20_CR61", "first-page": "252", "volume": "44", "author": "G Henriksen", "year": "2003", "unstructured": "Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44:252\u20139.", "journal-title": "J Nucl Med."}, {"key": "20_CR62", "first-page": "3120", "volume": "62", "author": "G Henriksen", "year": "2002", "unstructured": "Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62:3120\u20135.", "journal-title": "Cancer Res."}, {"key": "20_CR63", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1111/ijun.12059", "volume": "9", "author": "LM Lien", "year": "2015", "unstructured": "Lien LM, Tvedt B, Heinrich D. Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride. Int J Urol Nurs. 2015;9:3\u201313.", "journal-title": "Int J Urol Nurs."}, {"key": "20_CR64", "doi-asserted-by": "publisher", "first-page": "210686", "DOI": "10.1155/2013/210686", "volume": "2013", "author": "J El-Amm", "year": "2013", "unstructured": "El-Amm J, Freeman A, Patel N, Aragon-Ching JB. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer. 2013;2013:210686.", "journal-title": "Prostate Cancer."}, {"key": "20_CR65", "unstructured": "Saad F, Keizman D, O\u2019Sullivan JM, Carles J, Wirth M, Gillessen S, et al. Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP). Presented at: 2016 ASCO Annual Meeting; June 3\u20137, 2016, 2016; Chicago, IL."}, {"key": "20_CR66", "doi-asserted-by": "publisher", "first-page": "S484", "DOI": "10.1016/S0959-8049(16)31349-1", "volume": "51", "author": "O Sartor", "year": "2015", "unstructured": "Sartor O, Coleman RE, Morris MJ, Nilsson S, Shore N, Sweeney C, et al. Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA. Eur J Cancer. 2015;51:S484\u20135.", "journal-title": "Eur J Cancer."}, {"key": "20_CR67", "doi-asserted-by": "publisher", "first-page": "328", "DOI": "10.1111/j.1464-410X.2011.10818.x", "volume": "110", "author": "AO Sartor", "year": "2012", "unstructured": "Sartor AO, Fitzpatrick JM. Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int. 2012;110:328\u201335.", "journal-title": "BJU Int."}, {"key": "20_CR68", "doi-asserted-by": "publisher", "first-page": "151", "DOI": "10.1016/j.eururo.2016.07.032", "volume": "71", "author": "TM Beer", "year": "2017", "unstructured": "Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71:151\u20134.", "journal-title": "Eur Urol."}, {"key": "20_CR69", "doi-asserted-by": "publisher", "first-page": "983", "DOI": "10.1016/S1470-2045(12)70379-0", "volume": "13", "author": "K Fizazi", "year": "2012", "unstructured": "Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.", "journal-title": "Lancet Oncol."}], "container-title": ["Prostate Cancer and Prostatic Diseases"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/s41391-017-0020-y", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/s41391-017-0020-y.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/s41391-017-0020-y.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 8, 5]], "date-time": "2019-08-05T13:09:37Z", "timestamp": 1565010577000}, "score": 32.111366, "issued": {"date-parts": [[2018, 1, 3]]}, "references-count": 69, "journal-issue": {"published-print": {"date-parts": [[2018, 4]]}, "issue": "1"}, "alternative-id": ["20"], "URL": "http://dx.doi.org/10.1038/s41391-017-0020-y", "relation": {"cites": []}, "ISSN": ["1365-7852", "1476-5608"], "issn-type": [{"value": "1365-7852", "type": "print"}, {"value": "1476-5608", "type": "electronic"}], "subject": ["Urology", "Cancer Research", "Oncology"], "assertion": [{"value": "17 July 2017", "order": 1, "name": "received", "label": "Received", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "16 September 2017", "order": 2, "name": "accepted", "label": "Accepted", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "3 January 2018", "order": 3, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Compliance with ethical standards"}}, {"value": "C.P. has research support from Bayer and has received honoraria from and is an advisory board member and speaker for Bayer, Janssen, and AAA. A.H. is a consultant for Amgen, Astellas, Bayer, and Ipsen; is an advisory board member for Astellas, Ipsen, Janssen, and Sanofi; has received honoraria from Amgen, Astellas, Bayer, Ferring, Ipsen, Janssen, Pfizer, and Sanofi; and has received research grants from Amgen, Astellas, and Sanofi. S.N. is an advisory board member\u00a0for and has received honoraria from Bayer. N.S. is a consultant for and has received research grants from Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Pfizer, Sanofi, and Tolmar.", "order": 2, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Conflict of interest"}}]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T19:24:29Z", "timestamp": 1575401069217}, "reference-count": 18, "publisher": "Wiley", "issue": "6", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 650, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer"], "published-print": {"date-parts": [[2014, 3, 15]]}, "DOI": "10.1002/cncr.28485", "type": "journal-article", "created": {"date-parts": [[2013, 11, 20]], "date-time": "2013-11-20T17:55:25Z", "timestamp": 1384970125000}, "page": "818-823", "source": "Crossref", "is-referenced-by-count": 54, "title": ["No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period"], "prefix": "10.1002", "volume": "120", "author": [{"given": "Jennifer N.", "family": "Wu", "sequence": "first", "affiliation": [{"name": "Department of Urology; University of California at Davis, Davis Medical Center; Sacramento California"}]}, {"given": "Kari M.", "family": "Fish", "sequence": "additional", "affiliation": [{"name": "Cancer Registry of Greater California; Sacramento California"}]}, {"given": "Christopher P.", "family": "Evans", "sequence": "additional", "affiliation": [{"name": "Department of Urology; University of California at Davis, Davis Medical Center; Sacramento California"}]}, {"given": "Ralph W.", "family": "deVere White", "sequence": "additional", "affiliation": [{"name": "Department of Urology; University of California at Davis, Davis Medical Center; Sacramento California"}]}, {"given": "Marc A.", "family": "Dall'Era", "sequence": "additional", "affiliation": [{"name": "Department of Urology; University of California at Davis, Davis Medical Center; Sacramento California"}]}], "member": "311", "published-online": {"date-parts": [[2013, 11, 20]]}, "reference": [{"key": "10.1002/cncr.28485-BIB0001|cncr28485-cit-0001", "doi-asserted-by": "crossref", "first-page": "212", "DOI": "10.3322/caac.20121", "article-title": "Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths", "volume": "61", "author": "Siegel", "year": "2011", "journal-title": "CA Cancer J Clin"}, {"key": "10.1002/cncr.28485-BIB0002|cncr28485-cit-0002", "doi-asserted-by": "crossref", "first-page": "1310", "DOI": "10.1056/NEJMoa0810696", "article-title": "PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial", "volume": "360", "author": "Andriole", "year": "2009", "journal-title": "N Engl J Med"}, {"key": "10.1002/cncr.28485-BIB0003|cncr28485-cit-0003", "doi-asserted-by": "crossref", "first-page": "1320", "DOI": "10.1056/NEJMoa0810084", "article-title": "ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study", "volume": "360", "author": "Schroder", "year": "2009", "journal-title": "N Engl J Med"}, {"key": "10.1002/cncr.28485-BIB0004|cncr28485-cit-0004", "doi-asserted-by": "crossref", "first-page": "120", "DOI": "10.7326/0003-4819-157-2-201207170-00459", "article-title": "Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement", "volume": "157", "author": "Moyer", "year": "2012", "journal-title": "Ann Intern Med"}, {"key": "10.1002/cncr.28485-BIB0005|cncr28485-cit-0005", "doi-asserted-by": "crossref", "first-page": "5955", "DOI": "10.1002/cncr.27594", "article-title": "The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines", "volume": "118", "author": "Etzioni", "year": "2012", "journal-title": "Cancer"}, {"key": "10.1002/cncr.28485-BIB0006|cncr28485-cit-0006", "doi-asserted-by": "crossref", "first-page": "1164", "DOI": "10.1016/j.juro.2012.06.046", "article-title": "Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)", "volume": "188", "author": "Tangen", "year": "2012", "journal-title": "J Urol"}, {"key": "10.1002/cncr.28485-BIB0007|cncr28485-cit-0007", "doi-asserted-by": "crossref", "first-page": "774", "DOI": "10.1016/j.jamcollsurg.2012.12.036", "article-title": "Does enrollment in cancer trials improve survival?", "volume": "216", "author": "Chow", "year": "2013", "journal-title": "J Am Coll Surg"}, {"key": "10.1002/cncr.28485-BIB0008|cncr28485-cit-0008", "doi-asserted-by": "crossref", "first-page": "1502", "DOI": "10.1056/NEJMoa040720", "article-title": "TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", "volume": "351", "author": "Tannock", "year": "2004", "journal-title": "N Engl J Med"}, {"key": "10.1002/cncr.28485-BIB0009|cncr28485-cit-0009", "first-page": "233", "article-title": "Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population", "volume": "3", "author": "Engel-Nitz", "year": "2011", "journal-title": "Cancer Manag Res"}, {"key": "10.1002/cncr.28485-BIB0010|cncr28485-cit-0010", "doi-asserted-by": "crossref", "first-page": "706", "DOI": "10.1016/j.clon.2011.04.014", "article-title": "A population-based study of prostate cancer chemotherapy", "volume": "23", "author": "Harris", "year": "2011", "journal-title": "Clin Oncol (R Coll Radiol)"}, {"key": "10.1002/cncr.28485-BIB0011|cncr28485-cit-0011", "doi-asserted-by": "crossref", "first-page": "1995", "DOI": "10.1056/NEJMoa1014618", "article-title": "Abiraterone and increased survival in metastatic prostate cancer", "volume": "364", "author": "Bono", "year": "2011", "journal-title": "N Engl J Med"}, {"key": "10.1002/cncr.28485-BIB0012|cncr28485-cit-0012", "doi-asserted-by": "crossref", "first-page": "4854", "DOI": "10.1158/1078-0432.CCR-11-0815", "article-title": "Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response", "volume": "17", "author": "Ryan", "year": "2011", "journal-title": "Clin Cancer Res"}, {"key": "10.1002/cncr.28485-BIB0013|cncr28485-cit-0013", "doi-asserted-by": "crossref", "first-page": "411", "DOI": "10.1056/NEJMoa1001294", "article-title": "IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer", "volume": "363", "author": "Kantoff", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1002/cncr.28485-BIB0014|cncr28485-cit-0014", "doi-asserted-by": "crossref", "first-page": "1187", "DOI": "10.1056/NEJMoa1207506", "article-title": "Increased survival with enzalutamide in prostate cancer after chemotherapy", "volume": "367", "author": "Scher", "year": "2012", "journal-title": "N Engl J Med"}, {"issue": "6 pt 2", "key": "10.1002/cncr.28485-BIB0015|cncr28485-cit-0015", "doi-asserted-by": "crossref", "first-page": "S21", "DOI": "10.1097/01.ju.0000095025.03331.c6", "article-title": "CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE)", "volume": "170", "author": "Cooperberg", "year": "2003", "journal-title": "J Urol"}, {"key": "10.1002/cncr.28485-BIB0016|cncr28485-cit-0016", "doi-asserted-by": "crossref", "first-page": "1248", "DOI": "10.1093/jnci/dji248", "article-title": "Prostate cancer and the Will Rogers phenomenon", "volume": "97", "author": "Albertsen", "year": "2005", "journal-title": "J Natl Cancer Inst"}, {"key": "10.1002/cncr.28485-BIB0017|cncr28485-cit-0017", "doi-asserted-by": "crossref", "first-page": "1708", "DOI": "10.1056/NEJMoa1011967", "article-title": "SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer", "volume": "364", "author": "Bill-Axelson", "year": "2011", "journal-title": "N Engl J Med"}, {"key": "10.1002/cncr.28485-BIB0018|cncr28485-cit-0018", "doi-asserted-by": "crossref", "first-page": "203", "DOI": "10.1056/NEJMoa1113162", "article-title": "Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer", "volume": "367", "author": "Wilt", "year": "2012", "journal-title": "N Engl J Med"}], "container-title": ["Cancer"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.28485", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.28485", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 5]], "date-time": "2018-08-05T19:19:28Z", "timestamp": 1533496768000}, "score": 30.608553, "subtitle": ["Survival in Metastatic Prostate Cancer"], "issued": {"date-parts": [[2013, 11, 20]]}, "references-count": 18, "journal-issue": {"published-print": {"date-parts": [[2014, 3, 15]]}, "issue": "6"}, "URL": "http://dx.doi.org/10.1002/cncr.28485", "relation": {"cites": []}, "ISSN": ["0008-543X"], "issn-type": [{"value": "0008-543X", "type": "print"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T06:00:59Z", "timestamp": 1575352859196}, "reference-count": 8, "publisher": "Elsevier BV", "issue": "3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2019, 3, 1]], "date-time": "2019-03-01T00:00:00Z", "timestamp": 1551398400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "europeanurology.com", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Urology"], "published-print": {"date-parts": [[2019, 3]]}, "DOI": "10.1016/j.eururo.2018.11.003", "type": "journal-article", "created": {"date-parts": [[2018, 11, 16]], "date-time": "2018-11-16T13:42:03Z", "timestamp": 1542375723000}, "page": "e51-e52", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 6, "title": ["The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer"], "prefix": "10.1016", "volume": "75", "author": [{"given": "Joe M.", "family": "O'Sullivan", "sequence": "first", "affiliation": []}, {"given": "Daniel", "family": "Heinrich", "sequence": "additional", "affiliation": []}, {"given": "Nicholas D.", "family": "James", "sequence": "additional", "affiliation": []}, {"given": "Sten", "family": "Nilsson", "sequence": "additional", "affiliation": []}, {"given": "Piet", "family": "Ost", "sequence": "additional", "affiliation": []}, {"given": "Christopher C.", "family": "Parker", "sequence": "additional", "affiliation": []}, {"given": "Bertrand", "family": "Tombal", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Urology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0302283818308571?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0302283818308571?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 13]], "date-time": "2019-02-13T03:43:58Z", "timestamp": 1550029438000}, "score": 29.622063, "issued": {"date-parts": [[2019, 3]]}, "references-count": 8, "journal-issue": {"published-print": {"date-parts": [[2019, 3]]}, "issue": "3"}, "alternative-id": ["S0302283818308571"], "URL": "http://dx.doi.org/10.1016/j.eururo.2018.11.003", "ISSN": ["0302-2838"], "issn-type": [{"value": "0302-2838", "type": "print"}], "subject": ["Urology"], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer", "name": "articletitle", "label": "Article Title"}, {"value": "European Urology", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.eururo.2018.11.003", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "simple-article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T07:17:40Z", "timestamp": 1574320660093}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2009, 9, 1]], "date-time": "2009-09-01T00:00:00Z", "timestamp": 1251763200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2009, 9]]}, "DOI": "10.1016/s1359-6349(09)71381-3", "type": "journal-article", "created": {"date-parts": [[2009, 9, 3]], "date-time": "2009-09-03T12:32:43Z", "timestamp": 1251981163000}, "page": "406", "source": "Crossref", "is-referenced-by-count": 3, "title": ["7003 A double blind, randomised, dose finding, phase II, multicentre study of radium-223 for the treatment of patients with metastatic castration-refractory prostate cancer (CRPC): EudraCT number: 2005\u2013003680\u201322"], "prefix": "10.1016", "volume": "7", "author": [{"given": "C.", "family": "Parker", "sequence": "first", "affiliation": []}, {"given": "P.", "family": "Hoskin", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Pascoe", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Chodack", "sequence": "additional", "affiliation": []}, {"given": "J.M.", "family": "O'Sullivan", "sequence": "additional", "affiliation": []}, {"given": "J.R.", "family": "Germ\u00e1", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Lokna", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634909713813?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634909713813?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 17]], "date-time": "2018-12-17T11:20:45Z", "timestamp": 1545045645000}, "score": 29.598434, "issued": {"date-parts": [[2009, 9]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 9]]}, "issue": "2"}, "alternative-id": ["S1359634909713813"], "URL": "http://dx.doi.org/10.1016/s1359-6349(09)71381-3", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T14:32:43Z", "timestamp": 1574778763704}, "reference-count": 16, "publisher": "Wiley", "issue": "10", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 0, "content-version": "tdm"}], "funder": [{"name": "Bayer HealthCare Pharmaceuticals", "award": []}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Prostate"], "published-print": {"date-parts": [[2016, 7]]}, "DOI": "10.1002/pros.23180", "type": "journal-article", "created": {"date-parts": [[2016, 3, 23]], "date-time": "2016-03-23T11:07:59Z", "timestamp": 1458731279000}, "page": "905-916", "source": "Crossref", "is-referenced-by-count": 37, "title": ["Chemotherapy following radium-223 dichloride treatment in ALSYMPCA"], "prefix": "10.1002", "volume": "76", "author": [{"given": "Oliver", "family": "Sartor", "sequence": "first", "affiliation": [{"name": "Department of Medicine; Tulane Cancer Center; New Orleans Louisiana"}, {"name": "Department of Urology; Tulane Cancer Center; New Orleans Louisiana"}]}, {"given": "Peter", "family": "Hoskin", "sequence": "additional", "affiliation": [{"name": "Marie Curie Research Wing for Oncology; Mount Vernon Hospital Cancer Centre; Middlesex United Kingdom"}]}, {"given": "Robert E.", "family": "Coleman", "sequence": "additional", "affiliation": [{"name": "Academic Unit of Clinical Oncology, Weston Park Hospital; University of Sheffield; Sheffield United Kingdom"}]}, {"given": "Sten", "family": "Nilsson", "sequence": "additional", "affiliation": [{"name": "Department of Oncology; Karolinska University Hospital; Stockholm Sweden"}]}, {"given": "Nicholas J.", "family": "Vogelzang", "sequence": "additional", "affiliation": [{"name": "Department of Medical Oncology; University of Nevada School of Medicine and Comprehensive Cancer Centers of Nevada; Las Vegas Nevada"}]}, {"given": "Oana", "family": "Petrenciuc", "sequence": "additional", "affiliation": [{"name": "Department of Global Clinical Development; Bayer HealthCare Pharmaceuticals; Whippany New Jersey"}]}, {"given": "Karin", "family": "Staudacher", "sequence": "additional", "affiliation": [{"name": "Department of Study Management Europe; Bayer AS (formerly Algeta ASA); Oslo Norway"}]}, {"given": "Marcus", "family": "Thuresson", "sequence": "additional", "affiliation": [{"name": "Department of Biostatistics; Statisticon AB; Uppsala Sweden"}]}, {"given": "Christopher", "family": "Parker", "sequence": "additional", "affiliation": [{"name": "Academic Urology Unit; The Royal Marsden NHS Foundation Trust and Institute of Cancer Research; Sutton Surrey United Kingdom"}]}], "member": "311", "published-online": {"date-parts": [[2016, 3, 23]]}, "reference": [{"key": "10.1002/pros.23180-BIB0001|pros23180-cit-0001", "doi-asserted-by": "crossref", "first-page": "6250s", "DOI": "10.1158/1078-0432.CCR-06-0841", "article-title": "High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities", "volume": "12", "author": "Bruland", "year": "2006", "journal-title": "Clin Cancer Res"}, {"key": "10.1002/pros.23180-BIB0002|pros23180-cit-0002", "first-page": "3120", "article-title": "Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model", "volume": "62", "author": "Henriksen", "year": "2002", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.23180-BIB0003|pros23180-cit-0003", "first-page": "252", "article-title": "Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice", "volume": "44", "author": "Henriksen", "year": "2003", "journal-title": "J Nucl Med"}, {"key": "10.1002/pros.23180-BIB0004|pros23180-cit-0004", "doi-asserted-by": "crossref", "first-page": "213", "DOI": "10.1056/NEJMoa1213755", "article-title": "Alpha emitter radium-223 and survival in metastatic prostate cancer", "volume": "369", "author": "Parker", "year": "2013", "journal-title": "N Engl J Med"}, {"key": "10.1002/pros.23180-BIB0005|pros23180-cit-0005", "doi-asserted-by": "crossref", "first-page": "1513", "DOI": "10.1056/NEJMoa041318", "article-title": "Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer", "volume": "351", "author": "Petrylak", "year": "2004", "journal-title": "N Engl J Med"}, {"key": "10.1002/pros.23180-BIB0006|pros23180-cit-0006", "doi-asserted-by": "crossref", "first-page": "1502", "DOI": "10.1056/NEJMoa040720", "article-title": "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", "volume": "351", "author": "Tannock", "year": "2004", "journal-title": "N Engl J Med"}, {"key": "10.1002/pros.23180-BIB0007|pros23180-cit-0007", "doi-asserted-by": "crossref", "first-page": "1458", "DOI": "10.1056/NEJMoa1209096", "article-title": "Abiraterone in metastatic prostate cancer without previous chemotherapy", "volume": "368", "author": "Ryan", "year": "2013", "journal-title": "N Engl J Med"}, {"key": "10.1002/pros.23180-BIB0008|pros23180-cit-0008", "doi-asserted-by": "crossref", "first-page": "411", "DOI": "10.1056/NEJMoa1001294", "article-title": "Sipuleucel-T immunotherapy for castration-resistant prostate cancer", "volume": "363", "author": "Kantoff", "year": "2010", "journal-title": "N Engl J Med"}, {"key": "10.1002/pros.23180-BIB0009|pros23180-cit-0009", "doi-asserted-by": "crossref", "first-page": "424", "DOI": "10.1056/NEJMoa1405095", "article-title": "Enzalutamide in metastatic prostate cancer before chemotherapy", "volume": "371", "author": "Beer", "year": "2014", "journal-title": "N Engl J Med"}, {"key": "10.1002/pros.23180-BIB0010|pros23180-cit-0010", "doi-asserted-by": "crossref", "first-page": "1187", "DOI": "10.1056/NEJMoa1207506", "article-title": "Increased survival with enzalutamide in prostate cancer after chemotherapy", "volume": "367", "author": "Scher", "year": "2012", "journal-title": "N Engl J Med"}, {"key": "10.1002/pros.23180-BIB0011|pros23180-cit-0011", "doi-asserted-by": "crossref", "first-page": "1397", "DOI": "10.1016/S1470-2045(14)70474-7", "article-title": "Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial", "volume": "15", "author": "Hoskin", "year": "2014", "journal-title": "Lancet Oncol"}, {"issue": "Suppl 4", "key": "10.1002/pros.23180-BIB0012|pros23180-cit-0012", "doi-asserted-by": "crossref", "first-page": "iv261", "DOI": "10.1093/annonc/mdu336.13", "article-title": "Safety of radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer: A phase 1/2a clinical trial", "volume": "25", "author": "Morris", "year": "2014", "journal-title": "Ann Oncol"}, {"key": "10.1002/pros.23180-BIB0013|pros23180-cit-0013", "doi-asserted-by": "crossref", "first-page": "303", "DOI": "10.1038/pcan.2012.13", "article-title": "Toxicity in patients receiving adjuvant docetaxel+hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: A preplanned safety report of the SPCG-13 trial", "volume": "15", "author": "Kellokumpu-Lehtinen", "year": "2012", "journal-title": "Prostate Cancer Prostatic Dis"}, {"key": "10.1002/pros.23180-BIB0014|pros23180-cit-0014", "first-page": "1", "article-title": "Anemia in men with advanced prostate cancer: Incidence, etiology, and treatment", "volume": "6", "author": "Nalesnik", "year": "2004", "journal-title": "Rev Urol"}, {"key": "10.1002/pros.23180-BIB0015|pros23180-cit-0015", "doi-asserted-by": "crossref", "first-page": "284", "DOI": "10.1186/1471-2407-10-284", "article-title": "Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases", "volume": "10", "author": "Nieder", "year": "2010", "journal-title": "BMC Cancer"}, {"key": "10.1002/pros.23180-BIB0016|pros23180-cit-0016", "author": "Smith", "volume": "33", "year": "2015", "article-title": "ERA223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer", "journal-title": "J Clin Oncol", "DOI": "10.1200/jco.2015.33.15_suppl.tps5082", "doi-asserted-by": "crossref"}], "container-title": ["The Prostate"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.23180", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 9, 5]], "date-time": "2019-09-05T22:31:13Z", "timestamp": 1567722673000}, "score": 29.46381, "subtitle": ["Chemotherapy After Radium-223 in mCRPC"], "issued": {"date-parts": [[2016, 3, 23]]}, "references-count": 16, "journal-issue": {"published-print": {"date-parts": [[2016, 7]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1002/pros.23180", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0270-4137"], "issn-type": [{"value": "0270-4137", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T07:17:40Z", "timestamp": 1574320660264}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2009, 9, 1]], "date-time": "2009-09-01T00:00:00Z", "timestamp": 1251763200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2009, 9]]}, "DOI": "10.1016/s1359-6349(09)71396-5", "type": "journal-article", "created": {"date-parts": [[2009, 9, 3]], "date-time": "2009-09-03T12:32:43Z", "timestamp": 1251981163000}, "page": "412", "source": "Crossref", "is-referenced-by-count": 1, "title": ["7018 Alpha-emitting Radium-223: two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer"], "prefix": "10.1016", "volume": "7", "author": [{"given": "S.", "family": "Nilsson", "sequence": "first", "affiliation": []}, {"given": "L.", "family": "Franzen", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Parker", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Bolstad", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Ramdahl", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Thuresson", "sequence": "additional", "affiliation": []}, {"given": "O.", "family": "Bruland", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634909713965?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634909713965?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 17]], "date-time": "2018-12-17T11:20:40Z", "timestamp": 1545045640000}, "score": 29.45869, "issued": {"date-parts": [[2009, 9]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2009, 9]]}, "issue": "2"}, "alternative-id": ["S1359634909713965"], "URL": "http://dx.doi.org/10.1016/s1359-6349(09)71396-5", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T06:07:40Z", "timestamp": 1574402860625}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2011, 9, 1]], "date-time": "2011-09-01T00:00:00Z", "timestamp": 1314835200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2011, 9]]}, "DOI": "10.1016/s0959-8049(11)71959-1", "type": "journal-article", "created": {"date-parts": [[2011, 9, 26]], "date-time": "2011-09-26T09:44:13Z", "timestamp": 1317030253000}, "page": "S486", "source": "Crossref", "is-referenced-by-count": 1, "title": ["7008 POSTER DISCUSSION Twenty-four-month Safety Data From Phase II Studies of Radium-223 Chloride, a First-in-class Alpha-pharmaceutical With a Highly Favorable Safety Profile for Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases"], "prefix": "10.1016", "volume": "47", "author": [{"given": "S.", "family": "Nilsson", "sequence": "first", "affiliation": []}, {"given": "I.", "family": "Haugen", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Aksnes", "sequence": "additional", "affiliation": []}, {"given": "C.G.", "family": "O'Bryan-Tear", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Parker", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804911719591?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804911719591?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 29]], "date-time": "2018-11-29T21:24:47Z", "timestamp": 1543526687000}, "score": 29.45869, "issued": {"date-parts": [[2011, 9]]}, "references-count": 0, "alternative-id": ["S0959804911719591"], "URL": "http://dx.doi.org/10.1016/s0959-8049(11)71959-1", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:35:56Z", "timestamp": 1574890556444}, "reference-count": 0, "publisher": "BMJ", "issue": "6", "content-domain": {"domain": ["bmj.com"], "crossmark-restriction": true}, "short-container-title": ["ESMO Open"], "published-print": {"date-parts": [[2018, 10]]}, "abstract": "<jats:p><jats:boxed-text position=\"float\" orientation=\"portrait\"><jats:p><jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"https://soundcloud.com/bmjpodcasts/esmo-2018-presidential-symposium-radiotherapy-to-the-primary-tumor-in-metastatic-prostate-cancer\" ext-link-type=\"uri\">Click here to listen to the Podcast</jats:ext-link></jats:p></jats:boxed-text></jats:p>", "DOI": "10.1136/esmoopen-2018-000451", "type": "journal-article", "created": {"date-parts": [[2018, 10, 21]], "date-time": "2018-10-21T16:34:25Z", "timestamp": 1540139665000}, "page": "e000451", "update-policy": "http://dx.doi.org/10.1136/crossmarkpolicy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Report from the ESMO 2018 presidential symposium\u2014Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE"], "prefix": "10.1136", "volume": "3", "author": [{"given": "Chris", "family": "Parker", "sequence": "first", "affiliation": []}], "member": "239", "published-online": {"date-parts": [[2018, 10, 21]]}, "container-title": ["ESMO Open"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1136/esmoopen-2018-000451", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 10, 21]], "date-time": "2018-10-21T16:34:26Z", "timestamp": 1540139666000}, "score": 29.451256, "issued": {"date-parts": [[2018, 10]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2018, 10, 21]]}, "published-print": {"date-parts": [[2018, 10]]}, "issue": "6"}, "alternative-id": ["10.1136/esmoopen-2018-000451"], "URL": "http://dx.doi.org/10.1136/esmoopen-2018-000451", "ISSN": ["2059-7029"], "issn-type": [{"value": "2059-7029", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T01:33:06Z", "timestamp": 1574731986244}, "reference-count": 0, "publisher": "Wiley", "issue": "5", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Trends Urology & Men Health"], "published-print": {"date-parts": [[2015, 9]]}, "DOI": "10.1002/tre.486", "type": "journal-article", "created": {"date-parts": [[2015, 9, 30]], "date-time": "2015-09-30T09:45:56Z", "timestamp": 1443606356000}, "page": "40-42", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Radioisotopes reborn: radium-223 and its role in the management of prostate cancer"], "prefix": "10.1002", "volume": "6", "author": [{"given": "Chris", "family": "Parker", "sequence": "first", "affiliation": [{"name": "Royal Marsden NHS Trust; Sutton"}]}, {"given": "Joe", "family": "O'Sullivan", "sequence": "additional", "affiliation": [{"name": "Queen's University; Belfast"}]}, {"given": "Catherine", "family": "Heath", "sequence": "additional", "affiliation": [{"name": "University Hospitals; Southampton"}]}], "member": "311", "published-online": {"date-parts": [[2015, 9, 30]]}, "container-title": ["Trends in Urology & Men's Health"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Ftre.486", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 3, 27]], "date-time": "2017-03-27T21:29:52Z", "timestamp": 1490650192000}, "score": 28.995895, "subtitle": ["Reports"], "issued": {"date-parts": [[2015, 9]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2015, 9]]}, "issue": "5"}, "URL": "http://dx.doi.org/10.1002/tre.486", "archive": ["Portico"], "ISSN": ["2044-3730"], "issn-type": [{"value": "2044-3730", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T11:23:21Z", "timestamp": 1574335401640}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2007, 9, 1]], "date-time": "2007-09-01T00:00:00Z", "timestamp": 1188604800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer Supplements"], "published-print": {"date-parts": [[2007, 9]]}, "DOI": "10.1016/s1359-6349(07)71121-7", "type": "journal-article", "created": {"date-parts": [[2007, 12, 1]], "date-time": "2007-12-01T05:40:31Z", "timestamp": 1196487631000}, "page": "295", "source": "Crossref", "is-referenced-by-count": 1, "title": ["4054 POSTER Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC)"], "prefix": "10.1016", "volume": "5", "author": [{"given": "S.", "family": "Nilsson", "sequence": "first", "affiliation": []}, {"given": "L.", "family": "Franz\u00e9n", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Tyrrell", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Blom", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Tennvall", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Lennern\u00e4s", "sequence": "additional", "affiliation": []}, {"given": "D.C.", "family": "Johannessen", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Sokal", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Parker", "sequence": "additional", "affiliation": []}, {"given": "O.S.", "family": "Bruland", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer Supplements"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1359634907711217?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1359634907711217?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 2]], "date-time": "2019-01-02T15:53:26Z", "timestamp": 1546444406000}, "score": 28.96634, "issued": {"date-parts": [[2007, 9]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2007, 9]]}, "issue": "4"}, "alternative-id": ["S1359634907711217"], "URL": "http://dx.doi.org/10.1016/s1359-6349(07)71121-7", "ISSN": ["1359-6349"], "issn-type": [{"value": "1359-6349", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T22:09:51Z", "timestamp": 1574546991804}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2014, 9, 1]], "date-time": "2014-09-01T00:00:00Z", "timestamp": 1409529600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Oncology Nursing"], "published-print": {"date-parts": [[2014, 9]]}, "DOI": "10.1016/s1462-3889(14)70094-8", "type": "journal-article", "created": {"date-parts": [[2014, 9, 18]], "date-time": "2014-09-18T14:30:38Z", "timestamp": 1411050638000}, "page": "S21", "source": "Crossref", "is-referenced-by-count": 0, "title": ["76 Radium-223 dichloride (Ra-223) improves survival in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets): nursing roles in implementing this new treatment (tx) option"], "prefix": "10.1016", "volume": "18", "author": [{"given": "L.", "family": "Causer", "sequence": "first", "affiliation": []}, {"given": "B.", "family": "Johnson", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Sicari", "sequence": "additional", "affiliation": []}, {"given": "F.", "family": "Lavent", "sequence": "additional", "affiliation": []}, {"given": "L.M.E.", "family": "Lien", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Jensen", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Wahba", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Parker", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Oncology Nursing"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1462388914700948?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1462388914700948?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 29]], "date-time": "2018-09-29T17:25:20Z", "timestamp": 1538241920000}, "score": 28.750355, "issued": {"date-parts": [[2014, 9]]}, "references-count": 0, "alternative-id": ["S1462388914700948"], "URL": "http://dx.doi.org/10.1016/s1462-3889(14)70094-8", "ISSN": ["1462-3889"], "issn-type": [{"value": "1462-3889", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T00:11:13Z", "timestamp": 1574467873607}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "3", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2010, 11, 1]], "date-time": "2010-11-01T00:00:00Z", "timestamp": 1288569600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["International Journal of Radiation Oncology*Biology*Physics"], "published-print": {"date-parts": [[2010, 11]]}, "DOI": "10.1016/j.ijrobp.2010.07.886", "type": "journal-article", "created": {"date-parts": [[2010, 10, 1]], "date-time": "2010-10-01T09:19:07Z", "timestamp": 1285924747000}, "page": "S375-S376", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Clinical Experience and Radiation Safety of the First-in-Class Alpha-Pharmaceutical, Alpharadin (radium-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases"], "prefix": "10.1016", "volume": "78", "author": [{"given": "S.", "family": "Nilsson", "sequence": "first", "affiliation": []}, {"given": "C.", "family": "Parker", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Biggin", "sequence": "additional", "affiliation": []}, {"given": "O.", "family": "Bruland", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["International Journal of Radiation Oncology*Biology*Physics"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0360301610018602?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0360301610018602?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 7]], "date-time": "2018-12-07T17:53:25Z", "timestamp": 1544205205000}, "score": 28.14135, "issued": {"date-parts": [[2010, 11]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2010, 11]]}, "issue": "3"}, "alternative-id": ["S0360301610018602"], "URL": "http://dx.doi.org/10.1016/j.ijrobp.2010.07.886", "ISSN": ["0360-3016"], "issn-type": [{"value": "0360-3016", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 5]], "date-time": "2019-12-05T02:33:09Z", "timestamp": 1575513189833}, "reference-count": 52, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Current Opinion in Urology"], "published-print": {"date-parts": [[2019, 11]]}, "DOI": "10.1097/mou.0000000000000675", "type": "journal-article", "created": {"date-parts": [[2019, 9, 15]], "date-time": "2019-09-15T17:40:38Z", "timestamp": 1568569238000}, "page": "620-628", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Prostate radiotherapy in newly diagnosed metastatic prostate cancer"], "prefix": "10.1097", "volume": "29", "author": [{"given": "Adnan", "family": "Ali", "sequence": "first", "affiliation": []}, {"given": "Christopher C.", "family": "Parker", "sequence": "additional", "affiliation": []}, {"given": "Noel W.", "family": "Clarke", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["Current Opinion in Urology"], "language": "en", "link": [{"URL": "http://journals.lww.com/co-urology/Fulltext/10.1097/MOU.0000000000000675", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 25]], "date-time": "2019-09-25T15:04:50Z", "timestamp": 1569423890000}, "score": 28.103584, "subtitle": [""], "issued": {"date-parts": [[2019, 11]]}, "references-count": 52, "journal-issue": {"issue": "6"}, "URL": "http://dx.doi.org/10.1097/mou.0000000000000675", "ISSN": ["0963-0643"], "issn-type": [{"value": "0963-0643", "type": "print"}], "subject": ["Urology"]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T23:14:05Z", "timestamp": 1574723645488}, "reference-count": 14, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2017, 1, 1]], "date-time": "2017-01-01T00:00:00Z", "timestamp": 1483228800000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "start": {"date-parts": [[2016, 11, 17]], "date-time": "2016-11-17T00:00:00Z", "timestamp": 1479340800000}, "delay-in-days": 0, "content-version": "vor"}], "funder": [{"name": "Bayer Healthcare Pharmaceuticals Inc.", "award": []}], "content-domain": {"domain": ["clinicalkey.jp", "clinicalkey.com", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.fr", "ejcancer.com", "elsevier.com", "sciencedirect.com"], "crossmark-restriction": true}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2017, 1]]}, "DOI": "10.1016/j.ejca.2016.10.020", "type": "journal-article", "created": {"date-parts": [[2016, 12, 6]], "date-time": "2016-12-06T03:01:37Z", "timestamp": 1480993297000}, "page": "1-6", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "source": "Crossref", "is-referenced-by-count": 24, "title": ["Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial"], "prefix": "10.1016", "volume": "71", "author": [{"given": "Christopher", "family": "Parker", "sequence": "first", "affiliation": []}, {"given": "Lin", "family": "Zhan", "sequence": "additional", "affiliation": []}, {"given": "Paul", "family": "Cislo", "sequence": "additional", "affiliation": []}, {"given": "Jonathan", "family": "Reuning-Scherer", "sequence": "additional", "affiliation": []}, {"given": "Nicholas J.", "family": "Vogelzang", "sequence": "additional", "affiliation": []}, {"given": "Sten", "family": "Nilsson", "sequence": "additional", "affiliation": []}, {"ORCID": "http://orcid.org/0000-0002-8777-7343", "authenticated-orcid": false, "given": "Oliver", "family": "Sartor", "sequence": "additional", "affiliation": []}, {"given": "Joe M.", "family": "O'Sullivan", "sequence": "additional", "affiliation": []}, {"given": "Robert E.", "family": "Coleman", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804916325242?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804916325242?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 9, 6]], "date-time": "2018-09-06T05:51:59Z", "timestamp": 1536213119000}, "score": 28.035202, "issued": {"date-parts": [[2017, 1]]}, "references-count": 14, "alternative-id": ["S0959804916325242"], "URL": "http://dx.doi.org/10.1016/j.ejca.2016.10.020", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}], "assertion": [{"value": "Elsevier", "name": "publisher", "label": "This article is maintained by"}, {"value": "Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial", "name": "articletitle", "label": "Article Title"}, {"value": "European Journal of Cancer", "name": "journaltitle", "label": "Journal Title"}, {"value": "https://doi.org/10.1016/j.ejca.2016.10.020", "name": "articlelink", "label": "CrossRef DOI link to publisher maintained version"}, {"value": "article", "name": "content_type", "label": "Content Type"}, {"value": "\u00a9 2016 The Authors. Published by Elsevier Ltd.", "name": "copyright", "label": "Copyright"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T02:32:58Z", "timestamp": 1575253978330}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "6_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2018, 2, 20]]}, "abstract": "<jats:p> 259 </jats:p><jats:p> Introduction: RA-223 prolongs OS in BM-CRPC pts but predictive markers are lacking. We hypothesized that molecular profiling of plasma-derived extracellular vesicles (EVs) from BM-CRPC pts treated with RA-223 would predict efficacy and inform development of combinations. Methods: Paired baseline (BL) and end of treatment (EoT) blood samples were collected from 25 pts treated with RA-223. Pts were stratified by median OS into 3 groups: 1) 6.3 months (range 3.3-8.5, n=5 pts, UnFav OS), 2) 18.2 months (range 12.6-19.4, n=7 pts, Middle OS) and 3) 27.6 months (range 23.1-33.8, n=13 pts, Fav OS). EVs were isolated from plasma and analyzed for specific proteins and RNA transcripts. Marker profiles by domain and analytic method were determined in pts from the stratified OS groups. Results: At EoT, there is enrichment of RNA transcripts and proteins involved in regulating immune responses, DNA Damage Response (DDR) and bone metabolism (Table). By benchmarking molecular signatures in pts with UnFav Os and Fav OS, we could analyze the molecular profiles of pts in the Middle OS group and stratify them to UnFav OS or Fav OS groups. Conclusion: Plasma-based molecular markers are predictive for RA-223 efficacy. An association between OS and immune and DDR profiles in men with BM-CRPC may indicate mechanism of action and identify subsets most likely to benefit. These preliminary results provide rationale for combination therapy with RA-223 and immune-checkpoint blockade or PARP inhibition. Clinical trial information: NCT02135484. [Table: see text] </jats:p>", "DOI": "10.1200/jco.2018.36.6_suppl.259", "type": "journal-article", "created": {"date-parts": [[2018, 2, 26]], "date-time": "2018-02-26T21:14:10Z", "timestamp": 1519679650000}, "page": "259-259", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Molecular profiling of liquid biopsies from patients (pts) with bone metastatic castration-resistant prostate cancer (BM-CRPC) treated with radium-223 (RA-223) to reveal differential enrichment for markers that correlate with overall survival (OS)."], "prefix": "10.1200", "volume": "36", "author": [{"given": "Paul Gettys", "family": "Corn", "sequence": "first", "affiliation": [{"name": "UT MD Anderson Cancer Center, Houston, TX;"}]}, {"given": "Sumit Kumar", "family": "Subudhi", "sequence": "additional", "affiliation": [{"name": "UT MD Anderson Cancer Center, Houston, TX;"}]}, {"given": "John C.", "family": "Araujo", "sequence": "additional", "affiliation": [{"name": "UT MD Anderson Cancer Center, Houston, TX;"}]}, {"given": "Ioulia", "family": "Vardaki", "sequence": "additional", "affiliation": [{"name": "UT MD Anderson Cancer Center, Houston, TX;"}]}, {"given": "Ana", "family": "Aparicio", "sequence": "additional", "affiliation": [{"name": "UT MD Anderson Cancer Center, Houston, TX;"}]}, {"given": "Shi-Ming", "family": "Tu", "sequence": "additional", "affiliation": [{"name": "UT MD Anderson Cancer Center, Houston, TX;"}]}, {"given": "Lance C.", "family": "Pagliaro", "sequence": "additional", "affiliation": [{"name": "Mayo Clinic, Rochester, MN;"}]}, {"given": "Amado J.", "family": "Zurita", "sequence": "additional", "affiliation": [{"name": "UT MD Anderson Cancer Center, Houston, TX;"}]}, {"given": "Christopher", "family": "Logothetis", "sequence": "additional", "affiliation": [{"name": "UT MD Anderson Cancer Center, Houston, TX;"}]}, {"given": "Theocharis", "family": "Panaretakis", "sequence": "additional", "affiliation": [{"name": "UT MD Anderson Cancer Center, Houston, TX;"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.36.6_suppl.259", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:14:11Z", "timestamp": 1574889251000}, "score": 27.782768, "issued": {"date-parts": [[2018, 2, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2018, 2, 20]]}, "issue": "6_suppl"}, "alternative-id": ["10.1200/JCO.2018.36.6_suppl.259"], "URL": "http://dx.doi.org/10.1200/jco.2018.36.6_suppl.259", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T05:57:45Z", "timestamp": 1574402265904}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2011, 9, 1]], "date-time": "2011-09-01T00:00:00Z", "timestamp": 1314835200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Journal of Cancer"], "published-print": {"date-parts": [[2011, 9]]}, "DOI": "10.1016/s0959-8049(11)70100-9", "type": "journal-article", "created": {"date-parts": [[2011, 9, 23]], "date-time": "2011-09-23T19:58:24Z", "timestamp": 1316807904000}, "page": "3", "source": "Crossref", "is-referenced-by-count": 64, "title": ["Overall Survival Benefit of Radium-223 Chloride (Alpharadin\u2122) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)"], "prefix": "10.1016", "volume": "47", "author": [{"given": "C.", "family": "Parker", "sequence": "first", "affiliation": []}, {"given": "D.", "family": "Heinrich", "sequence": "additional", "affiliation": []}, {"given": "J.M.", "family": "O'Sullivan", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Fossa", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Chodacki", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Demkow", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Cross", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Bolstad", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Garcia-Vargas", "sequence": "additional", "affiliation": []}, {"given": "O.", "family": "Sartor", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Journal of Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0959804911701009?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0959804911701009?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 29]], "date-time": "2018-11-29T22:55:13Z", "timestamp": 1543532113000}, "score": 27.687424, "issued": {"date-parts": [[2011, 9]]}, "references-count": 0, "alternative-id": ["S0959804911701009"], "URL": "http://dx.doi.org/10.1016/s0959-8049(11)70100-9", "ISSN": ["0959-8049"], "issn-type": [{"value": "0959-8049", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:15:30Z", "timestamp": 1576797330241}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "15_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2019, 5, 20]]}, "DOI": "10.1200/jco.2019.37.15_suppl.e16513", "type": "journal-article", "created": {"date-parts": [[2019, 5, 27]], "date-time": "2019-05-27T16:09:26Z", "timestamp": 1558973366000}, "page": "e16513-e16513", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC)."], "prefix": "10.1200", "volume": "37", "author": [{"given": "Roberto", "family": "Alonzi", "sequence": "first", "affiliation": [{"name": "Mount Vernon Cancer Centre, Northwood, United Kingdom;"}]}, {"given": "Chris C.", "family": "Parker", "sequence": "additional", "affiliation": [{"name": "The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom;"}]}, {"given": "Nina", "family": "Tunariu", "sequence": "additional", "affiliation": [{"name": "The Royal Marsden NHS Foundation Trust, London, United Kingdom;"}]}, {"given": "Dow-Mu", "family": "Koh", "sequence": "additional", "affiliation": [{"name": "The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom;"}]}, {"given": "John", "family": "Staffurth", "sequence": "additional", "affiliation": [{"name": "Velindre Cancer Centre, Cardiff, United Kingdom;"}]}, {"given": "Matthew D.", "family": "Blackledge", "sequence": "additional", "affiliation": [{"name": "The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom;"}]}, {"given": "Anwar R.", "family": "Padhani", "sequence": "additional", "affiliation": [{"name": "Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, London, United Kingdom;"}]}, {"given": "Alison", "family": "Tree", "sequence": "additional", "affiliation": [{"name": "The Royal Marsden NHS Foundation Trust, London, United Kingdom;"}]}, {"given": "Helen", "family": "Stidwill", "sequence": "additional", "affiliation": [{"name": "The Royal Marsden NHS Foundation Trust, London, United Kingdom;"}]}, {"given": "Jessica", "family": "Finch", "sequence": "additional", "affiliation": [{"name": "Mount Vernon Cancer Centre, Northwood, United Kingdom;"}]}, {"given": "Peter", "family": "Chatfield", "sequence": "additional", "affiliation": [{"name": "Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom;"}]}, {"given": "Sophie", "family": "Perry", "sequence": "additional", "affiliation": [{"name": "Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom;"}]}, {"given": "Holly", "family": "Tovey", "sequence": "additional", "affiliation": [{"name": "Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom;"}]}, {"given": "Emma", "family": "Hall", "sequence": "additional", "affiliation": [{"name": "Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom;"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2019.37.15_suppl.e16513", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T20:43:44Z", "timestamp": 1574887424000}, "score": 27.372692, "issued": {"date-parts": [[2019, 5, 20]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2019, 5, 20]]}, "issue": "15_suppl"}, "alternative-id": ["10.1200/JCO.2019.37.15_suppl.e16513"], "URL": "http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e16513", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}